

Department of Respiratory and Critical Care Medicine,
Charité – Universitätsmedizin Berlin
Charitéplatz 1, 10117 Berlin, Germany

Tel.: +49 30 450 553 122
Fax: +49 30 450 7 553 876
E-Mail: martin.witzenrath@charite.de

OVERVIEW

Martin Witzenrath is physician scientist and chairman of the Department of Respiratory and Critical Care Medicine at Charité–Universitätsmedizin Berlin, Germany. His scientific work is dedicated to translational research on pneumonia and acute lung injury. His research group performs experimental research using *in vitro*, *ex vivo* and *in vivo* models, as well as observational and interventional clinical trials. Martin has published more than 260 peer-reviewed scientific papers, and received substantial third-party (including DFG, BMBF, foundations) research funding. The Witzenrath group has recently contributed to the development of several therapeutic strategies from bench to phase 2/3 trials by utilization of the translational pipeline established in-house, as well as through external collaborations. Martin is advisor for several companies in Biotech and Pharma industry.

CURRENT POSITION

- Medical Director of Charité Centrum12 (Internal Medicine and Dermatology)
- Director of the Department for Respiratory and Critical Care Medicine, incl. Sleep Medicine, Charité-Universitätsmedizin Berlin
- Professor (W3) for Pneumology, Charité - Universitätsmedizin Berlin

UNIVERSITY AND PROFESSIONAL CAREER

2017-2022 Deputy Director, Dept. for Infectious Diseases and Respiratory Medicine, Charité Berlin
2014-2022 Site Director, Dept. for Infectious Diseases and Respiratory Medicine, at Charité Campus Mitte
2012 Specialist for Pneumology, Charité Berlin
2011-2022 Senior physician, Dept. for Infectious Diseases and Respiratory Medicine, Charité Berlin
2010 Specialist for Internal Medicine, Charité Berlin
1994-2001 Study of Human Medicine, Justus-Liebig-University Giessen, Germany

SCIENTIFIC CAREER

2017 Appointment: W3-University Professorship for Pneumology, Charité Berlin
2017 Appointment: W3-University Professorship for Infectious Diseases, Medizinische Hochschule Hannover, (primo loco) *declined*
2016 Appointment: W3-University Professorship of Internal Medicine/Pneumology at the University of Lübeck (Chair of Pneumology and Director of the University Clinic of Pneumology; and Director of the Clinic at the Borstel Research Center; and Medical Director of the Leibniz Institute Borstel), *declined*
2012 Appointment: W2 university professorship for Pneumology / Respiratory Infections, Charité Berlin
2011 Appointment: W3 Endowed Professorship for Experimental Pneumology at Saarland University (primo loco), *declined*
2010 Habilitation and Venia Legendi, Charité Berlin
2005 Head of research group, Dept. Infectious Diseases and Respiratory Med, Charité Berlin
2001-2005 Post-Doc, Dept. of Infectious Diseases and Respiratory Medicine, Charité Berlin
2004 Doctorate "Dr. med." ("summa cum laude"), Justus Liebig University Giessen

SELECTED AWARDS AND ACTIVITIES

- Fellow of European Respiratory Society (FERS; Award for excellence in contribution to research, education and clinical leadership in respiratory medicine)
- Elected member of the "DFG Review Board Medicine" 2020-2028
- Ombudsman for Good Scientific Practice of the Charité Berlin
- Associated PI of the German Center for Lung Research (DZL)
- Award for extraordinary achievements in teaching, Faculty of Medicine, Charité Berlin (2013)
- Award of the German Society of Pneumology 2010

10 SELECTED PUBLICATIONS (past 3 years):

1. **Witzenrath M** & Welte T. A leap towards personalised therapy of acute lung injury. *Eur. Respir. J.* 60, (2022).
2. Felten M, ...**Witzenrath M**. Ventilator-induced lung injury is modulated by the circadian clock. *Am. J. Respir. Crit. Care Med.* (2022). IF 30.52
3. Erfinanda L, ...**Witzenrath M**, Kuebler WM. Loss of endothelial CFTR drives barrier failure and edema formation in lung infection and can be targeted by CFTR potentiation. *Sci. Transl. Med.* 14, (2022). IF 19.34
4. Vos T, ...**Witzenrath M**, ... *et al.* Estimated Global Proportions of Individuals with Persistent Fatigue, Cognitive, and Respiratory Symptom Clusters Following Symptomatic COVID-19 in 2020 and 2021. *JAMA* 328, 1604–1615 (2022). IF 157.37
5. Vlaar AP, **Witzenrath M**, ... *et al.* Anti-C5a antibody (vilobelimab) therapy for critically ill, invasively mechanically ventilated patients with COVID-19 (PANAMO): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. *Lancet Respir. Med.* 10, 1137–1146 (2022). IF 102.64
6. Lask A, ..., **Witzenrath M**. Adjunctive therapy with the Tie2 agonist Vasculotide reduces pulmonary permeability in *Streptococcus pneumoniae* infected and mechanically ventilated mice. *Sci Rep.* 15;12(1):15531 (2022). IF 4.6
7. Wendisch D, ..., **Witzenrath M**, ...*et al.* SARS-CoV-2 infection triggers profibrotic macrophage responses and lung fibrosis *Cell.* 22;184(26):6243-6261.e27 (2021). IF 41.6
8. **Witzenrath M**. & Kuebler WM The CypA-netics of ventilator-induced lung injury. *Am. J. Respir. Crit. Care Med.* 204, 385–387 (2021).
9. Ochs M,... **Witzenrath M**. Collapse induration of alveoli is an ultrastructural finding in a COVID-19 patient. *Eur. Respir. J.* 57, 2004165 (2021). IF 33.8
10. Nouailles G., ...**Witzenrath M**. Temporal omics analysis in Syrian hamsters unravel cellular effector responses to moderate COVID-19. *Nat. Commun.* 12, 1–18 (2021). IF 14.9

Google scholar (May 10, 2024): h-index: 64 citations: >16,900
peer reviewed publications: >250